Vitamin K2 Alters Bone Metabolism Markers in Hemodialysis Patients with a Low Serum Parathyroid Hormone Level | Zendy

Mariko Ochiai | Zendy; Ayumu Nakashima | Zendy; Norihisa Takasugi | Zendy; Kei Kiribayashi | Zendy; Tōru Kawai | Zendy; Koji Usui | Zendy; Kenichiro Shigemoto | Zendy; Naoki Hamaguchi | Zendy; Nobuoki Kohno | Zendy; Noriaki Yorioka | Zendy

Open Access

Vitamin K<sub>2</sub> Alters Bone Metabolism Markers in Hemodialysis Patients with a Low Serum Parathyroid Hormone Level

Author(s) -

Mariko Ochiai,

Ayumu Nakashima,

Norihisa Takasugi,

Kei Kiribayashi,

Tōru Kawai,

Koji Usui,

Kenichiro Shigemoto,

Naoki Hamaguchi,

Nobuoki Kohno,

Noriaki Yorioka

Publication year - 2010

Publication title -

nephron clinical practice

Language(s) - English

Resource type - Journals

ISSN - 1660-2110

DOI - 10.1159/000319642

Subject(s) - medicine , bone remodeling , parathyroid hormone , endocrinology , osteocalcin , n terminal telopeptide , hemodialysis , vitamin d and neurology , osteoprotegerin , vitamin d deficiency , alkaline phosphatase , calcium , chemistry , receptor , activator (genetics) , biochemistry , enzyme

A low level of intact parathyroid hormone (PTH) is an indicator of adynamic bone disease in hemodialysis patients, and is associated with a significant increase of all-cause mortality. Thus, effective treatment for adynamic bone disease is required. We previously investigated the effect of vitamin K₂ on adynamic bone disease. In this study, we assessed the efficacy of oral vitamin K₂ in a controlled trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research